RTP Mobile Logo
Year in Review — Proceedings from a Multitumor CME Symposium Focused on Key Clinical Presentations and Papers in Oncology
Released February 2014

Proceedings from a daylong symposium featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, multiple myeloma, non-small cell lung cancer and Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia. Including perspectives from Drs Rafael Fonseca, Nikhil C Munshi, Andrew M Evens, Sonali M Smith, Owen A O’Connor, Andrew D Zelenetz, Jyoti D Patel, Lecia V Sequist, Tanios Bekaii-Saab, Andrew X Zhu, Al B Benson III, Axel Grothey, Harold J Burstein, Hope S Rugo, Daniel J George and Matthew R Smith. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

    OVERVIEW OF ACTIVITY
    Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing clinical questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a daylong symposium combine the perspectives of 16 renowned investigators with a review of key recent presentations and publications across breast cancer, gastrointestinal cancers, genitourinary cancers, multiple myeloma, non-small cell lung cancer and Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia, to assist medical oncologists and hematologists in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES
    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary and select hematologic cancers.
    • Compare and contrast the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary and select hematologic cancers, and refer appropriate patients for study participation.
    • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Rafael Fonseca, MD
    Getz Family Professor of Cancer
    Chair, Department of Internal Medicine
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Intellikine, Lilly, Medtronic Inc, Millennium: The Takeda Oncology Company, Otsuka Pharmaceutical Co Ltd; Research Support: Celgene Corporation, Onyx Pharmaceuticals Inc.

    Nikhil C Munshi, MD
    Associate Professor of Medicine, Harvard Medical School
    Associate Director, Jerome Lipper Multiple Myeloma Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Celgene Corporation, Onyx Pharmaceuticals Inc; Consulting Agreement: Celgene Corporation; Ownership Interest: OncoPep.

    Andrew M Evens, DO, MSc
    Professor of Medicine
    Chief, Division of Hematology/Oncology
    Tufts University School of Medicine
    Director, Lymphoma Program
    Leader, Clinical Sciences Program
    Tufts Cancer Center
    Boston, Massachusetts

    Advisory Committee: Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc, Seattle Genetics; Contracted Research: Millennium: The Takeda Oncology Company, ZIOPHARM Oncology Inc.

    Sonali M Smith, MD
    Associate Professor
    Section of Hematology/Oncology
    Director, Lymphoma Program
    The University of Chicago
    Chicago, Illinois

    Advisory Committee: Allos Therapeutics, Amgen Inc, Celgene Corporation, Genentech BioOncology, Onyx Pharmaceuticals Inc, Seattle Genetics.

    Owen A O'Connor, MD, PhD
    Professor of Medicine and Developmental Therapeutics
    Director, Center for Lymphoid Malignancies
    Columbia University Medical Center
    College of Physicians and Surgeons
    NewYork-Presbyterian Hospital
    New York, New York

    Advisory Committee: Allos Therapeutics, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Onyx Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company.

    Andrew D Zelenetz, MD, PhD
    Vice Chair, Medical Informatics
    Department of Medicine
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    Consulting Agreements: Celgene Corporation, Cephalon Inc, Gilead Sciences Inc, GlaxoSmithKline, Sanofi, Seattle Genetics; Contracted Research: Genentech BioOncology, GlaxoSmithKline, Roche Laboratories Inc.

    Jyoti D Patel, MD
    Associate Professor of Medicine
    Northwestern University
    Feinberg School of Medicine
    Division of Hematology/Oncology
    Chicago, Illinois

    No real or apparent conflicts of interest to disclose.

    Lecia V Sequist, MD, MPH
    Associate Professor of Medicine, Harvard Medical School
    Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, GlaxoSmithKline, Merrimack Pharmaceuticals.

    Tanios Bekaii-Saab, MD
    Section Chief, Gastrointestinal Oncology
    Chair, OSUCCC Gastrointestinal Disease Research Group
    Associate Professor of Medicine and Pharmacology
    The Ohio State University—James Cancer Hospital
    Columbus, Ohio

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech BioOncology, Lilly, Sanofi; Contracted Research: Oncolytics Biotech Inc, Pfizer Inc..

    Andrew X Zhu, MD, PhD
    Director, Liver Cancer Research
    Massachusetts General Hospital Cancer Center
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Daiichi Sankyo Inc, Eisai Inc, Sanofi; Consulting Agreement: Sanofi; Contracted Research: Bristol-Myers Squibb Company, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Onyx Pharmaceuticals Inc.

    Al B Benson III, MD
    Professor of Medicine
    Associate Director for Clinical Investigations
    Robert H Lurie Comprehensive Cancer Center of
    Northwestern University
    Chicago, Illinois

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Precision Therapeutics Inc, Sanofi, Spectrum Pharmaceuticals Inc; Contracted Research: Amgen Inc, Astellas, Genentech BioOncology, Gilead Sciences Inc, Novartis Pharmaceuticals Corporation.

    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Contracted Research: Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech BioOncology, Lilly.

    Harold J Burstein, MD, PhD
    Associate Professor of Medicine
    Harvard Medical School
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No real or apparent conflicts of interest to disclose.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Contracted Research: Agensys Inc, a subsidiary of Astellas Pharma US, Amgen Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, MacroGenics Inc, Merck, Novartis Pharmaceuticals Corporation, Plexxikon Inc; Speakers Bureau: Genomic Health Inc.

    Daniel J George, MD
    Associate Professor of Medicine and Surgery
    Director of Genitourinary Oncology Program
    Duke Cancer Institute
    Durham, North Carolina

    Advisory Committee: Aveo Pharmaceuticals, Dendreon Corporation, Medivation Inc, Pfizer Inc, Sanofi, Viamet Pharmaceuticals Inc; Consulting Agreements: Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Exelixis Inc, Genentech BioOncology, Medivation Inc, Molecular Insight, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi, Teva Pharmaceutical Industries Ltd; Contracted Research: Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Dendreon Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

    Matthew R Smith, MD, PhD
    Professor of Medicine
    Harvard Medical School
    Director, Genitourinary Malignancies Program
    Massachusetts General Hospital
    Boston, Massachusetts

    Consulting Agreements and Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Algeta US, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Lilly, Medivation Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc and Seattle Genetics.

    Hardware/Software Requirements:

    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2014
    Expiration date: February 2015

Acknowledge and close

View video: